IPQ Inside the global regulatory dialogue

Lab Data Integrity at Issue in FDA Warning Letters Sent to China and India

Jun 13th, 2011

Please Log in to print the full article

Evidence of unreliable laboratory data has prompted the Office of Compliance at FDA’s Center for Drug Evaluation and Research (CDER) to issue warning letters over the past few months to drug manufacturers in China and...

You must be a paid subscriber to continue reading this article. If you are a paid subscriber, please Log in. If you are not a paid subscriber, please subscribe now.

©2021 IPQ Publications